Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
This paper reviews the results of three trials, HIV NAT002, AI455-053, and AIDS Clinical Trials Group (ACTG) 306, all of which evaluated the effectiveness of stavudine (d4T)-containing two-nucleoside combinations in antiretroviral-naive patients with human immunodeficiency virus type 1 (HIV-1) infection. The latter two studies directly compared d4T plus didanosine (ddI) or lamivudine (3TC) versus zidovudine (ZDV) plus each of these two nucleosides. The combined results of the three trials support the conclusion that d4T can be used effectively in combination with either ddI or 3TC to reduce viral loads and increase CD4 cell counts in patients with HIV-1 infection. The results of AI455-053 and ACTG 306 show further that combination of d4T with either ddI or 3TC is at least as effective as the use of ZDV with these nucleosides.
Fisher
M
M
Brighton Health Care NHS Trust, Brighton, UK.
D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016049:Didanosine / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D018119:Stavudine / Q000627:therapeutic use*; D019562:Viral Load
D019380:Anti-HIV Agents; D019259:Lamivudine; D018119:Stavudine; D016049:Didanosine